Irving Investors β Full Portfolio
5 tracked investments Β· listed companies and verified rows first
A pharmaceutical company that develops medicines and vaccines, with research pipelines and clinical trials aimed at new treatments.
BiotechHealthtech
Co-investorsHighlight CapitalAmgen VenturesBlackRockBlackstone Life SciencesClarus VenturesFrazier Healthcare Partners+4 more
LUMICKS develops life science research tools that measure and apply forces around biological interactions to link structural and 'omics analysis to functional outcomes at the molecular and cellular level.
BiotechDeep TechHardwareMedical Devices
Andrea(Co-founder & Chief Scientific Officer)Gerrit(Co-founder & Director of Product Management and Marketing)Hugo(CEO)Edmee(Chief Financial Officer)Hannah(HR Director)
Co-investorsLauxera Capital PartnersSoftBank Vision FundEuropean Investment BankGilde HealthcarePura Vida InvestmentsT. Rowe Price
Metagenomi Therapeutics is an in vivo genome editing company that uses genetic material sourced from natural environments (metagenomics) to develop a toolbox of editing tools for deletion, integration, and correction of genetic mutations.
BiotechDeep TechMedical DevicesBerkeley, US
Brian Thomas(Executive Officer, Director, Promoter)in
BoardAndrew Farquharson(Director)inJak Knowles(Director)
Co-investorsCatalio Capital Management, LPRA CapitalSozo VenturesAgent CapitalFrazier Life SciencesHumboldt+5 more
Model Medicines is an AI-powered biotechnology company that uses computation to discover and engineer small molecule drugs targeting disease-driving biological mechanisms.
AI & Machine LearningBiotechDeep TechDigital HealthLa Jolla, US
Daniel Haders(Executive Officer, Director)inDaniel Haders II, Ph.D(Founder, CEO)inSean Russell(Founder, Chief Operating Officer)inKip Quackenbush(Executive Officer, Director)inMarlon Evans(Executive Officer, Director)in
Other
Tracked investments with no reachable website or further public details β typically companies that wound down, renamed, or were absorbed.
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.